CIML NK Cell Infusion + IL-2 (post-transplant relapse)

Current understanding

To be populated as evidence accumulates.

2026-06-17 — Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation: cross-connection with post-transplant-relapse-ciml-nk: Both pages describe CIML NK + IL-2 protocols post-transplant; this trial extends the approach from salvage-of-relapse to preemptive relapse prevention. (novelty: 4)
2026-04-03 — A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation: Phase 1 trial (early-phase, no results yet) evaluating cytokine-induced memory-like (CIML) NK cell infusion combined with IL-2 in AML/MDS/MPN patients relapsing after haploidentical or HLA-matched allogeneic HCT; primary endpoints are safety and feasibility. (novelty: 4)